| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/10-1/50 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Vasohibin-2, Vasohibin-like protein, VASH2, VASHL |
| Entrez GeneID | 79805 |
| WB Predicted band size | 40.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | This VASH2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 216-245 amino acids from the C-terminal region of human VASH2. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4条关于VASH2抗体的简要参考文献(虚构示例，实际文献需根据具体数据库检索)：
1. **"VASH2 promotes hepatocellular carcinoma progression through EMT and PI3K/Akt signaling"**
- **作者**: Hiraki Y, et al.
- **摘要**: 研究利用VASH2抗体检测肝癌组织中VASH2蛋白表达，发现其高表达与肿瘤转移和不良预后相关，并证实VASH2通过调控上皮间质转化(EMT)和PI3K/Akt通路促进侵袭。
2. **"Vasohibin-2 as a novel biomarker for breast cancer angiogenesis"**
- **作者**: Zhang Y, et al.
- **摘要**: 通过免疫组化(VASH2抗体)分析乳腺癌样本，发现VASH2在肿瘤血管内皮细胞中高表达，且与微血管密度增加和患者生存期缩短显著相关，提示其作为抗血管治疗靶点的潜力。
3. **"VASH2 regulates gastric cancer stemness via TGF-β pathway"**
- **作者**: Wang J, et al.
- **摘要**: 研究使用VASH2抗体进行Western blot和免疫荧光实验，发现VASH2通过激活TGF-β信号通路维持胃癌干细胞特性，沉默VASH2可抑制肿瘤球形成和体内成瘤能力。
4. **"Targeting VASH2 in colorectal cancer: A therapeutic strategy"**
- **作者**: Shen L, et al.
- **摘要**: 利用VASH2抗体筛选结直肠癌患者组织，结合体外实验证明VASH2抑制剂可协同增强化疗敏感性，机制涉及VEGF通路抑制和凋亡诱导。
建议通过PubMed或Google Scholar以“VASH2 antibody”或“Vasohibin-2 function”为关键词检索真实文献。
The vasohibin-2 (VASH2) antibody is a tool used to detect and study VASH2. a protein implicated in angiogenesis and cancer progression. VASH2 belongs to the vasohibin family, which includes VASH1 and VASH2. both regulating blood vessel formation. Unlike VASH1. which suppresses angiogenesis, VASH2 promotes endothelial cell migration and tube formation, often acting synergistically with pro-angiogenic factors like VEGF. Structurally, VASH2 contains a conserved carboxypeptidase-like domain and interacts with small vasohibin-binding protein (SVBP) to form an enzyme complex with tubulin tyrosine carboxypeptidase activity, influencing microtubule dynamics.
VASH2 is overexpressed in various cancers, including hepatocellular carcinoma and glioblastoma, correlating with tumor aggressiveness, metastasis, and poor prognosis. Its role in pathological angiogenesis and tumor microenvironment remodeling makes it a potential therapeutic target. The VASH2 antibody enables researchers to investigate its expression patterns, subcellular localization, and functional mechanisms in vitro and in vivo. Neutralizing antibodies are also explored for anti-angiogenic therapies. However, VASH2's dual roles in physiological and pathological contexts require careful study to avoid off-target effects. Overall, the VASH2 antibody serves as a critical reagent for unraveling its biological significance and translational potential.
×
